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abstract
PURPOSENivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial
(ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metastatic cervical, vaginal,
or vulvar cancers.
PATIENTS AND METHODS Patients received nivolumab 240 mg every 2 weeks. Although patients with unknown
human papillomavirus status were enrolled, patients known to have human papillomavirus–negative tumors
were ineligible. The primary end point was objective response rate. Duration of response (DOR), progression-free
survival, and overall survival were secondary end points. Safety and patient-reported outcomes were exploratory
end points.
RESULTS Twenty-four patients (cervical, n5 19; vaginal/vulvar, n5 5) were enrolled. Most patients had received
prior systemic therapy for metastatic disease (cervical, 78.9%; vaginal/vulvar, 80.0%). Objective response rates
were 26.3% (95% CI, 9.1 to 51.2) for cervical cancer and 20.0% (95% CI, 0.5 to 71.6) for vaginal/vulvar
cancers. At a median follow-up of 19.2 months, median DOR was not reached (range, 23.3 to 29.5+ months; +
indicates a censored observation) in the five responding patients in the cervical cohort; the DOR was 5.0 months
in the single responding patient in the vaginal/vulvar cohort. Median overall survival was 21.9 months (95% CI,
15.1 months to not reached) among patients with cervical cancer. Any-grade treatment-related adverse events
were reported in 12 of 19 patients (63.2%) in the cervical cohort and all five patients in the vaginal/vulvar cohort;
there were no treatment-related deaths. In the cervical cohort, nivolumab treatment generally resulted in
stabilization of patient-reported outcomes associated with health status and health-related quality of life.
CONCLUSION The efficacy of nivolumab in patients with recurrent/metastatic cervical and vaginal or vulvar
cancers is promising and warrants additional investigation. No new safety signals were identified with nivolumab
treatment in this population.
J Clin Oncol 37:2825-2834. © 2019 by American Society of Clinical Oncology
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INTRODUCTION
Almost all cervical cancers1 and many vaginal2 and
vulvar3 cancers are the result of human papilloma-
virus (HPV) infection. Despite the availability of
cytologic screening, cervical cancer remains a sig-
nificant cause of morbidity and mortality.4 First-line
treatment of patients with recurrent/metastatic cer-
vical cancer and those presenting with stage IVB
disease includes platinum-based chemotherapy
or paclitaxel/topotecan5; adding bevacizumab to
these chemotherapy regimens has been shown to
improve survival.6,7 Response rates associated with
first-line treatment of recurrent/metastatic cervical
cancer ranged from 13% to 46% for chemotherapy
alone6,8-10 to approximately 50% for bevacizumab-
containing regimens.6 Median overall survival (OS)
values ranged from 6.5 to 13.3 months for
chemotherapy-only regimens6,8-10 to 16.8 months for
bevacizumab-containing regimens.6 Responses to
second-line treatments for recurrent/metastatic cer-
vical cancer are infrequent and transient, and there is
no established standard of care.5,11 Vaginal and
vulvar cancers are rare, and there are no effective
chemotherapy regimens for recurrent vaginal or
vulvar cancer12,13; few clinical trials include these
patient populations.
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Virus-induced cancers are attractive targets for immuno-
therapy because viral proteins are strong immune stimu-
lants.14 In June 2018, pembrolizumab received accelerated
approval for the treatment of patients with recurrent/-
metastatic cervical cancers expressing programmed death-
ligand 1 (PD-L1) postchemotherapy.15 Nivolumab is a fully
human immunoglobulin G4 programmed death-1 im-
mune checkpoint inhibitor that is approved for the
treatment of various cancers.16 CheckMate 358 (Clin-
icalTrials.gov identifier: NCT02488759) is an ongoing
phase I/II study evaluating nivolumab-based therapy in
virus-associated tumors. We report on a cohort of 24
patients with recurrent/metastatic cervical, vaginal, or
vulvar cancers receiving nivolumab monotherapy in
CheckMate 358.
PATIENTS AND METHODS
Study Design, Patients, and Treatment
CheckMate 358 is a multicenter, open-label, multicohort
phase I/II trial investigating nivolumab-based therapies in
patients with virus-associated solid tumors in the neo-
adjuvant or recurrent/metastatic setting. In the recurrent/
metastatic cervical and vaginal/vulvar carcinoma cohorts,
patients received nivolumab monotherapy (240 mg in-
travenously every 2 weeks for # 2 years) until dis-
ease progression, unacceptable toxicity, or withdrawal of
consent.
Eligible patients were nonpregnant, nonbreastfeeding
women 18 years of age and older with an Eastern Co-
operative Oncology Group performance status of 0 or 1 and
a histologically confirmed diagnosis of squamous cell
carcinoma of the cervix, vagina, or vulva measurable by
computed tomography, magnetic resonance imaging, and/
or physical examination, according to Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1. Patients had
recurrent/metastatic disease with two or fewer prior sys-
temic therapies in the metastatic setting. For patients with
accessible lesions, submission of fresh or archival tumor
tissue was required. Whereas patients with unknown HPV
status could be enrolled, patients with known HPV-negative
tumors were not eligible for inclusion. Other key exclusion
criteria were active brain or leptomeningeal metastases,
another invasive malignancy active within the previous
3 years, active autoimmune disease, or needing systemic
treatment with immunosuppressive medications within
2 weeks of study drug administration.
Study End Points
The primary end point was investigator-assessed objective
response rate (ORR), defined as the proportion of patients
with a best overall response of complete response (CR) or
partial response, per RECIST version 1.1. Secondary end
points included duration of response (DOR; defined for
confirmed responses as the time from first documented
response to first documented tumor progression or death
from any cause), OS (time from first dose to death from any
cause), and progression-free survival (PFS; time from first
dose to first documented tumor progression or death from
any cause). Exploratory end points included safety and
patient-reported outcomes (PROs) using the European
Organization for Research and Treatment of Cancer Quality
of Life Questionnaire-C30 (EORTC QLQ-C30; to assess
cancer-specific health-related quality of life) and EuroQoL
five dimensions (EQ-5D; to assess overall health status).
Physical examination was performed within 14 days before
the first study dose and every 2 weeks thereafter. Tumor
assessments by computed tomography or magnetic reso-
nance imaging were conducted within 35 days before the
first study dose, every 8 weeks during the first year, and
every 12 weeks thereafter until disease progression or
treatment discontinuation. Survival was monitored at the
first follow-up assessment 35 days after the last dose,
80 days after the first follow-up assessment, and every
3 months thereafter. Safety was monitored throughout the
study and until 100 days after the last dose. Patients were
observed for ongoing treatment-related adverse events
(TRAEs) until resolved, returned to baseline/deemed irre-
versible, or lost to follow-up, withdrawal of study consent, or
start of a subsequent anticancer therapy. Adverse events
were assessed using worst grade per National Cancer In-
stitute Common Terminology Criteria for Adverse Events
version 4 by system organ class and Medical Dictionary for
Regulatory Activities preferred terms. PROs were assessed
before dosing, on day 1 of week 1, every 8 weeks until week
34, and every 12 weeks thereafter.
HPV Testing
HPV positivity was defined by a US Food and Drug
Administration–approved test or other well-validated
commercially available test comprising in situ hybridiza-
tion (ISH), real-time polymerase chain reaction, or immu-
nohistochemistry. HPV status per institutional testing
before enrollment was documented. If not available, HPV
testing was performed retrospectively on a fresh tumor
biopsy obtained at study screening, using ISH, for the
following subtypes: 6, 11, 16, 18, and 33.
PD-L1 Expression
Tumor cell PD-L1 expression was assessed in pretreatment
(archival or fresh) tumor biopsy specimens with the use of
a validated, automated immunohistochemical assay (PD-
L1 IHC 28-8 pharmDx; Dako–Agilent Technologies, Santa
Clara, CA) using the rabbit antihuman PD-L1 clone 28-8.17
Tumor cell PD-L1 expression was defined as the per-
centage of tumor cells exhibiting plasma membrane
staining at any intensity. PD-L1 expression by tumor cells
plus tumor-associated immune cells was determined using
a combined positive score (defined as the number of PD-
L1+ cells, including tumor cells, lymphocytes, and mac-
rophages, divided by the total number of viable tumor cells
3 100) for a post hoc analysis.18
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Study Oversight
The protocol was approved by an institutional review board
or independent ethics committee at each site before study
activation. The study was conducted in accordance with
Good Clinical Practice guidelines as defined by the In-
ternational Conference on Harmonisation, and in accor-
dance with the ethical principles of the European Union
Directive and US Code of Federal Regulations. All patients
provided written informed consent in accordance with the
Declaration of Helsinki. Bristol-Meyers Squibb policy on
data sharing may be found at https://www.bms.com/
researchers-and-partners/independent-research/data-sharing-
request-process.html.
Statistical Analysis
An enrollment of 23 patients was planned for the cohort of
patients with recurrent/metastatic cervical, vaginal, or
vulvar carcinoma. If the true ORR is 20%, the probability of
detecting three or more responses among 23 patients
would be 86.7%; if the true ORR is 30%, the probability
would be 98.4%. Tumor responses were evaluated in
patients who received one or more doses of the study drug
and who had either one or more in-study time point with all
baseline target lesion(s) assessed, or clinical progression or
death before any in-study tumor assessment. ORR was
summarized by binomial response rates and their corre-
sponding 95% exact CIs by the Clopper-Pearson method.19
DOR, OS, and PFS were estimated using Kaplan-Meier
techniques.20 DOR was summarized for all treated pa-
tients who achieved confirmed partial response or CR using
the Kaplan-Meier product-limit method. Median DOR, along
with two-sided 95% CIs using the Brookmeyer and Crowley
method,21 was also calculated. Median PFS or OS and
corresponding 95% CIs were constructed based on a log-log
transformed CI for the survivor function. Rates at fixed time
points were derived from the Kaplan-Meier estimate, and
corresponding CIs were derived based on the Greenwood
formula for variance derivation and on log-log transformation
applied on the survivor function.22 Safety was summarized
for all treated patients using descriptive statistics. PRO data
were summarized using descriptive statistics. The database
lock for this analysis was July 13, 2018.
RESULTS
Patient, Tumor, and Treatment Characteristics
Twenty-four patients with squamous cell carcinomas were
enrolled in the gynecologic cancer cohort of CheckMate
358, 19 with cervical carcinoma and five with vaginal/vulvar
carcinoma. The median age was 51.0 years (range, 28 to
75 years) in the cervical cohort and 59.0 years (range, 40 to
78 years) in the vaginal/vulvar cohort (Table 1). Most pa-
tients had stage IV disease at enrollment (cervical, 84.2%;
vaginal/vulvar, 60.0%) and had received prior systemic
therapy for metastatic disease (78.9% and 80.0%,
respectively).The most common sites of metastatic disease
seen in 40% or more of patients were lymph node and lung
in the cervical cohort and lymph node, skin/soft tissue, and
lung in the vaginal/vulvar cohort.
Among patients with evaluable HPV status (cervical, 18 of
19 patients; vaginal/vulvar, five of five patients), 15 (83.3%)
and two (40.0%) patients, respectively, had tumors positive
for HPV subtypes 6, 11, 16, 18, or 33 (Table 1). Among
patients with quantifiable tumor cell PD-L1 expression
(cervical, 16 of 19 patients; vaginal/vulvar, four of five
patients), 10 (62.5%) and four (100.0%), respectively, had
1% or more tumor cell PD-L1 expression. When PD-L1
expression was assessed on tumor cells plus tumor-
associated immune cells, all patients with quantifiable
PD-L1 expression had a combined positive score of 1 or
greater (not shown).
The median duration of nivolumab treatment was
5.6 months (range, 0.5 to 31.4+ months; + indicates pa-
tient still receiving therapy) in the cervical cohort and
6.7 months (range, 2.1 to 7.5 months) in the vaginal/vulvar
cohort. The median follow-up was 19.2 months (range, 1.4
to 31.4 months) and 10.3 months (range, 3.9 to 23.7
months), respectively. At the time of the database lock,
three patients (15.8%) in the cervical cohort and none in
the vaginal/vulvar cohort continued to receive treatment
(Appendix Table A1; Appendix Fig A1, online only).
Efficacy
ORRs were 26.3% (95% CI, 9.1% to 51.2%) in the cervical
cohort and 20.0% (95% CI, 0.5% to 71.6%) in the vaginal/
vulvar cohort (Table 2). The disease control rates were
68.4% (95% CI, 43.4% to 87.4%) and 80.0% (95% CI,
28.4% to 99.5%) in the cervical and vaginal/vulvar cohorts,
respectively. Of the five responding patients in the cervical
cohort, three patients continued to receive treatment and
remain in response as of database lock. These three patients
were white, ranged in age from 33 to 75 years, had HPV-
positive tumors, and had undergone prior surgery and ra-
diotherapy; two patients had received prior systemic ther-
apies for recurrent/metastatic disease. One patient had
tumor cell PD-L1 expression of 1% or greater, one had tumor
cell PD-L1 expression less than 1%, and one patient was not
evaluable. Median DOR was not reached (range, 23.3 to
29.5+ months; + indicates a censored observation) in the
cervical cohort; DOR was 5.0 months in the single
responding patient in the vaginal/vulvar cohort. Subgroup
analyses in the cervical cohort by tumor cell PD-L1 ex-
pression and prior systemic therapy for metastatic disease
are listed in Appendix Table A2 (online only). Owing to small
patient numbers, response rates were not analyzed within
these subgroups in the vaginal/vulvar cohort. Best change
from baseline in tumor burden and changes in tumor burden
over time for individual patients are presented in Figure 1.
Time to response andDORare presented in Appendix Figure
A1. An example of a CR observed in a patient with recurrent
stage IIB cervical cancer is shown in Figure 2.
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TABLE 1. Baseline Patient and Tumor Characteristics
Characteristic
Cervical
Cancer
(n = 19)
Vaginal/Vulvar
Cancersa
(n = 5)
Median age (range), years 51.0 (28-75) 59.0 (40-78)
Region
United States/Canada 1 (5.3) 0
Europe 18 (94.7) 5 (100.0)
Race
White 17 (89.5) 5 (100.0)
American Indian or Alaska Native 1 (5.3) 0
Other 1 (5.3) 0
AJCC stage,b
IIB 1 (5.3) 1 (20.0)
IIIB or IIIC 2 (10.5) 1 (20.0)
IVA or IVB 16 (84.2) 3 (60.0)
ECOG performance status
0 10 (52.6) 1 (20.0)
1 8 (42.1) 4 (80.0)
Not reported 1 (5.3) 0
HPV status,c
Evaluable 18 (94.7) 5 (100.0)
Positive 15 (83.3) 2 (40.0)
Negative 3 (16.7) 3 (60.0)
Not tested 1 (5.3) 0
Tumor cell PD-L1 expressiond
Quantifiable 16 (84.2) 4 (80.0)
$ 1% 10 (62.5) 4 (100.0)
, 1% 6 (37.5) 0
Not testede/not evaluablef 3 (15.8) 1 (20.0)
Sites of metastatic diseaseg
Lymph node 12 (63.2) 3 (60.0)
Lung 8 (42.1) 2 (40.0)
Pelvis 5 (26.3) 1 (20.0)
Other 5 (26.3) 0
Uterus 3 (15.8) 0
Peritoneum 2 (10.5) 0
Bone with no soft tissue
component
2 (10.5) 0
Bone with soft tissue component 1 (5.3) 0
Chest wall 1 (5.3) 1 (20.0)
Skin/soft tissue 1 (5.3) 3 (60.0)
Gastric 0 1 (20.0)
Liver 0 1 (20.0)
Time from initial diagnosis to study
entry
# 1 year 5 (26.3) 3 (60.0)
. 1 year 14 (73.7) 2 (40.0)
(continued in next column)
TABLE 1. Baseline Patient and Tumor Characteristics (continued)
Characteristic
Cervical
Cancer
(n = 19)
Vaginal/Vulvar
Cancersa
(n = 5)
Prior radiotherapy 17 (89.5) 4 (80.0)
Prior lines of systemic therapy
0 0 1 (20.0)
1 8 (42.1) 3 (60.0)
2 8 (42.1) 1 (20.0)
3 3 (15.8) 0
Prior systemic therapy in the
metastatic setting or with
radiation in the neoadjuvant
or adjuvant settingh
Platinum 19 (100.0) 4 (80.0)
Cisplatin 15 (78.9) 3 (60.0)
Carboplatin 11 (57.9) 1 (20.0)
Paclitaxel 12 (63.2) 0
Bevacizumab 6 (31.6) 0
Topotecan 5 (26.3) 0
Capecitabine 1 (5.3) 1 (20.0)
Other 1 (5.3) 0
Mitomycin 0 1 (20.0)
Fluorouracil 0 1 (20.0)
Docetaxel 0 1 (20.0)
Prior lines of systemic therapy for
metastatic disease
0 4 (21.1) 1 (20.0)
1 8 (42.1) 3 (60.0)
2 7 (36.8) 1 (20.0)
Time from completion of most recent
prior therapy to study entry
# 6 months 12 (63.2) 3 (60.0)
. 6 to # 12 months 1 (5.3) 1 (20.0)
. 12 months 2 (10.5) 1 (20.0)
Unknown/not reported 4 (21.1) 0
NOTE. Data are No. (%) unless otherwise indicated.
Abbreviations: AJCC, American Joint Committee on Cancer; ECOG,
Eastern Cooperative Oncology Group; HPV, human papillomavirus;
PD-L1, programmed death ligand-1.
aTwo patients had vaginal cancer and three patients had vulvar
cancer.
bAligned with Fe´de´ration Internationale de Gyne´cologie et
d’Obste´trique staging.
cRetrospective HPV testing included the following subtypes: 6, 11,
16, 18, and 33.
dTumor cell PD-L1 expression was defined as the percentage of
tumor cells exhibiting plasma membrane staining at any intensity.
eSample not available.
fLess than 100 viable tumor cells present on the stained slide.
gTwelve patients with cervical cancer and three patients with vaginal/
vulvar cancer had lesions at more than one site, including target and
nontarget lesions.
hSome patients received more than one type of therapy.
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In the cervical cohort, median OS was 21.9 months (95%
CI, 15.1 months to not reached) and the 12-month and 24-
month OS rates were 77.5% (95% CI, 50.5% to 91.0%)
and 49.8% (95% CI, 23.6% to 71.3%; Fig 3A), re-
spectively. Median PFS was 5.1 months (95% CI, 1.9 to 9.1
months) and 26.3% (95% CI, 9.6% to 46.8%) of patients
were progression free at 12 months (Fig 3B). Owing to
the small size of the vaginal/vulvar cohort, median OS and
PFS were not calculated. At 12 months and 18 months,
40.0% (95% CI, 5.2% to 75.3%) and 20.0% (95% CI,
0.8% to 58.2%) of patients with vaginal/vulvar cancers,
respectively, were alive; at 6 months, 40.0% (95% CI, 5.2%
to 75.3%) of patients were progression free. On the basis of
a subgroup analysis, OS was not considerably affected by
PD-L1 status or prior systemic cancer therapy for meta-
static disease in the cervical cohort (Appendix Fig A2,
online only).
Safety
TRAEs are listed in Table 3. The most common TRAE was
diarrhea in the cervical cohort (four of 19 patients; 21.1%)
and decreased appetite in the vaginal/vulvar cohort (two of
five patients; 40.0%). One patient (5.3%) in the cervical
cohort discontinued treatment owing to a TRAE (grade 3
pneumonitis), which occurred 2 days after the last (25th)
dose of nivolumab and resolved 14 days later with in-
travenous corticosteroids. No treatment-related deaths were
reported in either cohort. Three patients (15.8%) reported
serious grade 3 to 4 TRAEs in the cervical cohort (one each:
diarrhea, hepatocellular injury, and pneumonitis); these
were reported on study days 16, 267, and 367, respectively.
No serious TRAEs were reported in the vaginal/vulvar cohort.
Most select TRAEs (defined as adverse events with potential
immunologic causes) were grade 1 to 2 in severity. The most
common select TRAEs of any grade in the cervical cohort
were GI (21.1%) and skin (21.1%) reactions; in the vaginal/
vulvar cohort, skin-related and endocrine reactions reported
in one of five patients each (20.0%) were most common.
Grade 3 to 4 select TRAEs reported in the cervical cohort
included GI and pulmonary events in 1 patient each; none
were reported in the vaginal/vulvar cohort.
Patient-Reported Outcomes
In the cervical cohort, 18 of 19 patients (94.7%) at baseline
and all 14 patients (100%) at week 9 answered the EORTC
QLQ-C30 and EQ-5D questionnaires. For EORTC QLQ-C30,
complete data in 10 or more patients were available at
baseline (n = 16) and week 9 (n = 13). On the basis of
EORTC QLQ-C30 scores, global health status was stable at
week 9 compared with baseline, as were physical func-
tioning, emotional functioning, and social functioning;
however, clinically meaningful deterioration was noted in
role functioning and cognitive functioning. Patients re-
ported clinically meaningful improvement in pain and
constipation, clinically meaningful deterioration in fatigue,
and stability with regard to nausea and vomiting, dyspnea,
insomnia, appetite loss, diarrhea, and financial difficulties.
For EQ-5D, complete data in 10 or more patients were
available at baseline (n = 18) and week 9 (n = 13). Patients
were stable at week 9 compared with baseline on the basis
of EQ-5D utility scores and EQ-5D visual analog scale
scores. PRO data were not reported for the vaginal/vulvar
cohort owing to small patient numbers.
DISCUSSION
There is currently no standard of care for recurrent/met-
astatic cervical cancer that has progressed on systemic
chemotherapy and bevacizumab. In CheckMate 358,
TABLE 2. Tumor Responses According to RECIST, version 1.1
Response
Cervical Cancer
(n = 19)
Vaginal/Vulvar Cancers
(n = 5)
Best overall response (assessed by investigator)*
Complete response 3 (15.8) 0
Partial response 2 (10.5) 1 (20.0)
Stable disease 8 (42.1) 3 (60.0)
Progressive disease 6 (31.6) 1 (20.0)
ORR, No. (%; 95% CI)† 5 (26.3; 9.1 to 51.2) 1 (20.0; 0.5 to 71.6)
Disease control rate,‡ No. (%; 95% CI)† 13 (68.4; 43.4 to 87.4) 4 (80.; 28.4 to 99.5)
Median time to response (range), months 1.7 (1.6-1.9) 2.0 (2.0-2.0)
Median duration of response (range), months§ NR (23.3-29.5k) 5.0 (5.0-5.0)
NOTE. Data are No. (%) unless otherwise indicated.
Abbreviations: NR, not reached; ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors, version 1.1.
*Assessed by investigators per RECIST.
†On the basis of the Clopper and Pearson method.
‡Proportion of patients with a complete response, a partial response, or stable disease.
§Median computed using Kaplan-Meier method.
kCensored observation.
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nivolumab resulted in an ORR of 26.3% among patients
with recurrent/metastatic cervical cancer. Responses were
durable; at a median follow-up of 19.2 months, median
DOR was not reached. Median OS was 21.9 months, with
12-month and 24-month OS rates of 77.5% and 49.8%,
respectively. Median PFS was 5.1 months, and the 12-
month PFS rate was 26.3% without regard to PD-L1 status.
All five patients who responded had an unconfirmed CR,
with three of the five CRs confirmed on subsequent eval-
uation. For most PRO measures, nivolumab treatment was
associated with stabilization with regard to overall health
status and cancer-specific health-related quality of life. To
our knowledge, this study provides the longest reported
follow-up for patients with advanced cervical cancer treated
with a programmed death-1 or PD-L1 inhibitor.
Pembrolizumab was recently approved for the treatment of
PD-L1–expressing recurrent/metastatic cervical cancer
postchemotherapy on the basis of results from the
phase II KEYNOTE-158 trial (ClinicalTrials.gov identifier:
NCT02628067), in which an ORR of 14.3% was reported
in PD-L1–positive cervical cancers.15,23 In an earlier phase
Ib study (KEYNOTE-028; ClinicalTrials.gov identifier:
NCT02054806) that evaluated pembrolizumab in patients
with similar eligibility, ORR was 17% and median OS was
11 months.24 In the NRG-GY002 (ClinicalTrials.gov iden-
tifier: NCT02257528) study, nivolumab treatment resulted
in an ORR of 4% in a patient population (n = 25) similar to
that of CheckMate 358.25
The current standard for the management of meta-
static vaginal/vulvar cancers is driven by the approach
taken for cervical cancer, owing to the lack of robust data
or clinical trials evaluating novel treatments. The ma-
jority of patients with recurrent/metastatic vaginal/vulvar
cancers are typically treated with platinum combinations;
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FIG 1. Characteristics
of treatment response.
(A) Maximum change
from baseline in the
sum of tumor target
lesion diameters, accord-
ing to Response Evalua-
tion Criteria in Solid
Tumors, version 1.1
(RECIST). Tumor reduction
data (bars) correspond to
maximum change from
baseline in only target
lesions and not to best
overall response. (B) Ki-
netics of change in tu-
mor burden over time on
therapy. Dotted hori-
zontal lines in panels A
and B indicate 30%
target lesion reduction
(consistent with a re-
sponse in the absence
of new lesions) and
20% increase (consis-
tent with progressive
disease), per RECIST.
(*) Bars with asterisks
represent confirmed
responses (complete
response or partial re-
sponse). Bars without
asterisks represent un-
confirmed responses.
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however, the efficacy of platinum-based treatments in
this patient population has not been demonstrated, and
there are no approved systemic therapies. In Check-
Mate 358, nivolumab showed promising activity in
a small cohort of five patients with recurrent/metastatic
vaginal/vulvar cancers, with one partial responder
(patient with HPV-negative vulvar cancer), 12-month
and 18-month OS rates of 40.0% and 20.0%, re-
spectively, and a 6-month PFS rate of 40.0%. Check-
Mate 358 is the only immunotherapy trial to report
outcomes of patients with metastatic vaginal/vulvar
cancers.
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FIG 2. Computed tomography scans at baseline and cycle 77 are shown for a 75-year-old white woman with human papillomavirus–positive
metastatic cervical cancer with tumor cell programmed death-ligand 1 expression of 1% or greater. This patient was initially diagnosed in April
2014 with stage IIB disease (per Fe´de´ration Internationale de Gyne´cologie et d’Obste´trique staging) and underwent chemoradiotherapy with
cisplatin. She was diagnosed with recurrent metastatic disease in October 2015 and enrolled in CheckMate 358 in November 2015 with stage IV
disease and an Eastern Cooperative Oncology Group performance status of 0. Target lesions at baseline included mediastinal lymph node lesion
(20 mm), subcarinal lymph node lesion (25 mm), and right lung lesion (19 mm). The patient received her first dose of nivolumab on December 3,
2015. Her best overall response was complete response (CR), documented in November 2017 after 50 cycles of treatment. She was cancer-free
as of January 8, 2019, and is continuing in this study.
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Nivolumab demonstrated a manageable safety profile in
patients with cervical, vaginal, or vulvar cancers. Any-grade
TRAEs were reported in 12 of 19 patients (63.2%) in the
cervical cohort and all five patients in the vaginal/vulvar
cohort; grade 3 to 4 TRAEs were reported in four patients
(21.1%) and 0 patients, respectively. There were no
treatment-related mortalities, and no new safety signals for
nivolumab were observed. This experience compares fa-
vorably with adverse effects typically observed with che-
motherapies used in this patient population.8-11
In this study, 18 of 19 patients (83.3%) with cervical
cancer, both patients with vaginal cancer, and no patients
among the three patients with vulvar cancer tested positive
for HPV. However, it is known that almost all cervical
cancers1 and a proportion of vulvar (40%)3 and vaginal
cancers (75%)2 are caused by HPV infection. The lower-
than-expected rate of HPV positivity in this study might
be attributed to the varied sensitivity of different HPV
tests at different sites and the low coverage of HPV
subtypes by the ISH assay used.26 Additional studies in
larger cohorts will be needed to examine the influence
that the presence/genotype of HPV and other factors
might have on the efficacy of nivolumab in gynecologic
cancers.
It should be noted that patient numbers were small in this
study, thus limiting subgroup analyses. Furthermore, tumor
response was not assessed by independent radiologic
review. Nonetheless, the tumor response rate, durability of
response, and OS results are encouraging, especially
considering that approximately 80% of patients had un-
dergone prior systemic therapies for recurrent/metastatic
disease.
TABLE 3. TRAEs (in $ 10% of patients) and Select Treatment-Related Adverse Events
Event
Cervical Cancer
(n = 19)
Vaginal/Vulvar Cancers
(n = 5)
Any Grade Grade 3-4 Any Grade Grade 3-4
Any TRAE 12 (63.2) 4 (21.1) 5 (100.0) 0
TRAEs leading to discontinuation 1 (5.3)* 1 (5.3)* 0 0
TRAEs reported in $ 10% of patients†
Diarrhea 4 (21.1) 1 (5.3) 0 0
Fatigue 3 (15.8) 0 1 (20.0) 0
Pneumonitis 2 (10.5) 1 (5.3) 0 0
Abdominal pain 2 (10.5) 0 1 (20.0) 0
Stomatitis 2 (10.5) 0 0 0
Dry eye 2 (10.5) 0 0 0
Arthralgia 2 (10.5) 0 1 (20.0) 0
Decreased appetite 1 (5.3) 0 2 (40.0) 0
Any serious TRAE 3 (15.8) 3 (15.8) 0 0
Diarrhea 1 (5.3) 1 (5.3) 0 0
Hepatocellular injury 1 (5.3) 1 (5.3) 0 0
Pneumonitis 1 (5.3) 1 (5.3) 0 0
Any serious TRAE leading to discontinuation 1 (5.3)* 1 (5.3)* 0 0
Select TRAEs
GI 4 (21.1) 1 (5.3) 0 0
Skin 4 (21.1) 0 1 (20.0) 0
Pulmonary 2 (10.5) 1 (5.3) 0 0
Endocrine 1 (5.3) 0 1 (20.0) 0
Hepatic 1 (5.3) 0 0 0
Renal 1 (5.3) 0 0 0
Hypersensitivity/infusion reactions 0 0 0 0
NOTE. Data are No. (%). Includes events reported from the time of the first dose of study drug to 100 days after the last dose.
Abbreviation: TRAE, treatment-related adverse event.
*Discontinuation because of treatment-related pneumonitis.
†Events are listed in order of frequency for any-grade TRAEs in patients with cervical cancer. Individual patients may have had more than one
TRAE.
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In conclusion, the efficacy of nivolumab monotherapy in
CheckMate 358 in patients with recurrent/metastatic cer-
vical cancer was promising. Responses were durable; at
a median follow-up of 19.2 months, three of 19 (16%)
patients were continuing to receive treatment, and median
DOR was not reached. The activity noted in vulvar/vaginal
cancer also warrants additional investigation. Given the
lack of effective therapy and low survival rates for patients
with metastatic disease in these gynecologic cancers, the
results reported here are of strong clinical interest and
underscore the growing role of immune checkpoint in-
hibitors in this patient population.
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APPENDIX
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FIG A1. Treatment exposure, time to response, and duration of response in all patients. Patient 2 in the cervical
cohort was documented as having progressive disease 5 days after last nivolumab dose; this information is not
included in the figure as it was not captured in the data cut reported in the manuscript.
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FIG A2. Overall survival (OS) in patients with cervical cancer by (A) Tumor cell programmed death ligand 1 (PD-L1)
expression (defined as the percentage of tumor cells exhibiting plasma membrane staining at any intensity) and (B)
prior systemic cancer therapy (PSCT) for metastatic disease. Owing to the high percentage of censored responses,
median and rate estimators may be misleading. CI, confidence interval; NR, not reached. (*) Point estimates are
derived from Kaplan-Meier analyses; 95% CIs are derived from Greenwood’s formula.
TABLE A1. Patient Disposition
Outcome
Cervical Cancer
(n = 19)
Vaginal/Vulvar Cancers
(n = 5)
Patients continuing to receive study treatment 3 (15.8) 0
Patients not continuing to receive study treatment 16 (84.2) 5 (100.0)
Reason for treatment discontinuation
Disease progression 14 (87.5) 4 (80.0)
Adverse event unrelated to study drug 1 (6.3) 1 (20.0)
Study drug toxicity 1 (6.3) 0
NOTE. Data are No. (%).
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